

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Addiese: COMMISSIONER FOR PATENTS P O Box 1450 Alexandra, Virginia 22313-1450 www.wepto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/522,110	02/24/2005	Qishou Xu	CU-4057 BWH	3549
26530 7590 01/12/2010 LADAS & PARRY LLP 224 SOUTH MICHIGAN AVENUE			EXAMINER	
			GOON, SCARLETT Y	
SUITE 1600 CHICAGO, IL 60604			ART UNIT	PAPER NUMBER
			1623	
			MAIL DATE	DELIVERY MODE
			01/12/2010	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)			
Examiner-Initiated Interview Summary	10/522,110	XU ET AL.			
Examiner-initiated interview Summary	Examiner	Art Unit			
	SCARLETT GOON	1623			
All Participants:	Status of Application: per	ding			
(1) <u>SCARLETT GOON</u> .	(3)				
(2) Ms. Zareefa B. Flener, Applicants' representative.	(4)				
Date of Interview: 4 January 2010	Time: <u>11:37 am</u>				
Type of Interview:	ant's representative)				
Part I.					
Rejection(s) discussed: None					
Claims discussed: None					
Prior art documents discussed: None					
Part II. SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL See Continuation Sheet	RAL NATURE OF WHAT WAS	DISCUSSED:			
Part III.					
 It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability. It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above. 					
/SCARLETT GOON/ Examiner, Art Unit 1623	applicant/Applicant's Representat	ive Signature – if appropriate)			

Application No. 10/522,110

Continuation of Substance of Interview including description of the general nature of what was discussed: Ms. Flener, Applicants' representative, was contacted regarding potential patentable subject matter. The Examiner indicated to Ms. Flener that the remarks/arguments filed in response to the outstanding Office Action was not sufficient to put the case in condition for allowance. More specifically, the Examiner noted to Ms. Flener that Applicants argue that the claimed composition and method had superior long-acting properly that was unexpected. However, in the absence of a Declaration showing the unexpected results, between the 5'-lauric ester of riboflavin and other positional isomeric esters of riboflavin (such as on the 2-, 3- or 4- positions), and between the 5'-lauric ester of riboflavin and other esters differing in the chain length, the instantly claimed methods are still considered prima facie obvious over the teachings of the prior art. The Examiner queried as to whether Applicants would be able to submit such a Declaration. Ms. Flener indicated she would discuss the matter with Applicants.